As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Baricitinib for treating active autoantibody-positive systemic lupus erythematosus ID3997. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Decision Selected
Process TAG
ID number 3997

Timeline

Key events during the development of the guidance:

Date Update
01 April 2022 Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Baricitinib for treating active autoantibody-positive systemic lupus erythematosus ID3997. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual